TL;DR — Omega-3s are the most extensively studied anti-inflammatory compound in medicine, with over 30,000 published studies behind them. The REDUCE-IT trial showed high-dose EPA reduced major cardiovascular events by 25% in high-risk patients — the largest cardiovascular benefit ever demonstrated for a supplement. Tier A for cardiovascular and inflammatory endpoints; Tier B for direct longevity outcomes.
Overview: EPA/DHA vs ALA — why conversion matters
Omega-3 fatty acids come in two functionally different forms: the plant-derived precursor ALA (found in flaxseed, walnuts) and the marine-derived, biologically active forms EPA and DHA (found in fish oil). Human conversion of ALA to EPA/DHA is inefficient — typically under 10% — which is why fish-oil-derived EPA/DHA, not ALA, carries the human trial evidence discussed here.
Structure explains half of what these molecules do. EPA's 20-carbon chain carries five cis double bonds, and each cis bond puts a fixed kink in the chain — five kinks total. Kinked chains can't pack tightly against one another, and that inability to pack is exactly what keeps a cell membrane fluid rather than rigid. The same polyunsaturated chain is also the enzymatic substrate for the resolvins and other specialized pro-resolving mediators covered below — so a single molecule is doing structural work inside the membrane and signaling work out of it.
Primary hallmarks targeted: Chronic inflammation · Altered intercellular communication · Telomere attrition · Dysbiosis
Bhatt et al. 2018 (PMID 30145934, New England Journal of Medicine, REDUCE-IT trial): 4 g/day icosapentaenoic acid (EPA-only) reduced major adverse cardiovascular events by 25% versus mineral oil placebo in high-risk patients — the largest cardiovascular benefit ever demonstrated for a supplement. A meta-analysis (PMID 32835509, Critical Reviews in Food Science and Nutrition 2021) confirms EPA/DHA reduce inflammatory biomarkers via specialized pro-resolving mediators. A separate study (PMID 22245710, Brain, Behavior, and Immunity 2012) found omega-3 supplementation preserved leukocyte telomere length in healthy adults versus placebo.
SPM resolution axis — active resolution, not suppression
| Reported effect | Trial evidence | Hallmark link |
|---|---|---|
| ↓major adverse cardiovascular events 25% | REDUCE-IT (PMID 30145934) | Chronic inflammation |
| ↓hs-CRP and IL-6 | SPM meta-analysis (PMID 32835509) | Chronic inflammation |
| Preserved telomere length vs placebo | PMID 22245710 | Telomere attrition |
| Reduced depressive symptoms | Neuroinflammatory mechanism studies | Altered intercellular communication |
EPA and DHA are enzymatic precursors to resolvins, protectins, and maresins — a class of lipid mediators that actively terminate inflammatory cascades by clearing cellular debris, reprogramming macrophages from a pro-inflammatory (M1) to a resolving (M2) phenotype, and restoring tissue homeostasis. This is mechanistically distinct from passive anti-inflammatory agents that simply block a single pathway.
What the REDUCE-IT trial actually tested
REDUCE-IT used high-dose EPA-only (icosapentaenoic acid, the prescription form Vascepa) in a high-cardiovascular-risk population already on statin therapy. The 25% event reduction applies most directly to that population — a lower-risk healthy adult should weigh the SPM/inflammation-marker data as the more broadly applicable case, not assume an identical magnitude of cardiovascular benefit.
REDUCE-IT trial design and outcomes
| Study type | Population | Key reported outcome | Tier |
|---|---|---|---|
| REDUCE-IT (PMID 30145934) | High-CV-risk adults, n=8,179 | ↓25% major adverse cardiovascular events | A |
| SPM meta-analysis (PMID 32835509) | Mixed populations | ↓hs-CRP, ↓IL-6 via resolution mediators | A |
| Telomere study (PMID 22245710) | Healthy older adults | Preserved leukocyte telomere length vs placebo | A |
← Swipe for more columns →
Consensus: Tier A across cardiovascular, inflammatory, and telomere-preservation endpoints — one of the most extensively replicated evidence bases of any compound in this library. Tier B remains the honest label only for direct all-cause-longevity endpoints, which no trial has directly tested.
Where omega-3 disappoints
- The headline trial is contested. REDUCE-IT's 25% benefit used a mineral-oil placebo that may itself have raised events in the control arm — inflating the apparent effect. A separate large trial of EPA+DHA (STRENGTH) found no cardiovascular benefit. The truth sits somewhere between. - The benefit is concentrated in high-risk, high-triglyceride patients. A healthy adult with normal lipids who already eats fish should expect a much smaller effect than the trial numbers suggest. - High doses carry a real atrial-fibrillation signal. Several trials found more new-onset AFib on high-dose omega-3 — this is not a free "more is better" compound.
What would change this grade. Omega-3 is A for cardiovascular and inflammatory endpoints in high-risk patients — not a proven general-population longevity intervention. A clean trial with an inert placebo replicating REDUCE-IT would settle the placebo controversy; a positive healthy-population outcome trial would broaden the grade. It would narrow toward B for low-risk users if STRENGTH-type nulls prove more representative.
Telomere data: omega-3 and telomerase activation
The telomere-preservation finding (PMID 22245710) is a real, published human RCT result — omega-3 supplementation was associated with preserved leukocyte telomere length relative to placebo over the study period in healthy older adults. This sits alongside, not instead of, the cardiovascular and inflammatory evidence — omega-3's case spans multiple hallmarks simultaneously rather than one narrow mechanism.
Dosing: 2–4 g EPA+DHA combined; form (rTG, krill, standard)
| Parameter | Recommendation | |
|---|---|---|
| Dose | 2–4 g combined EPA+DHA daily | |
| BioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → | ~73%, requires fat-containing meal | |
| Timing | AM/PM, split with meals | |
| Form | Re-esterified triglyceride (rTG) form achieves ~70% superior absorption vs standard ethyl ester form | |
| Pharmacokinetics | Plasma half-life ≈37 h, but membrane incorporation builds over weeks and persists for months | This is why the omega-3 index plateaus over ~12 weeks, not days — judge the effect at the 12-week retest, not early |
What dose and form fits your risk profile?
Do you have established cardiovascular disease or high cardiovascular risk?
4 g/day EPA-dominant form (matching REDUCE-IT dosing) — discuss with your physician, especially if already on statin therapy
2 g combined EPA+DHA daily as a general inflammation/telomere-support dose
Scheduled surgery within 1–2 weeks — omega-3s increase bleeding time; pause supplementation beforehand
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Monitoring: omega-3 index, hs-CRP, ApoB, triglycerides
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Omega-3 index | Rising toward optimal range | Baseline, 12 wk | Flat → verify dose, form, and compliance with fat co-ingestion |
| hs-CRP | <1.0 mg/L | Baseline, 12 wk | Persistently high → review broader inflammation drivers |
| Triglycerides | Trending down | Baseline, 12 wk | Rising → review total diet, not just omega-3 dose |
| ApoB | Stable or improving | Baseline, 12 wk | Rising → full lipid panel review with physician |
← Swipe for more columns →
Bleeding risk and sourcing quality matter
- High doses (>3 g/day) can increase bleeding time — real risk, not theoretical.
- Choose third-party-tested products for oxidation and heavy-metal contamination — fish oil quality varies widely between brands.
- Take with food to reduce reflux and fishy aftertaste, and to improve absorption.
- Avoid starting or continue with caution if scheduled surgery is within 1–2 weeks.
- Consult a physician if on blood thinners (warfarin, aspirin, clopidogrel).
- Consult a physician if you have a known fish or shellfish allergy.
- Consult a physician if you have a history of atrial fibrillation.
Who should skip omega-3
- A history of atrial fibrillation — high-dose omega-3 has a dose-dependent AFib signal; discuss dose with your physician. - Anyone with surgery scheduled within 1–2 weeks — it increases bleeding time; pause beforehand. - Low-risk adults who already eat fatty fish regularly — the incremental benefit over diet is small; spend the budget elsewhere.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Resveratrol | Resveratrol's AMPK/SIRT1 activation and omega-3's SPM-mediated resolution address inflammation from two independent angles | Resveratrol module |
| Sulforaphane | Sulforaphane activates the NRF2 antioxidant gene program; omega-3 resolves inflammation via a separate SPM pathway — orthogonal coverage of the same hallmark | Sulforaphane module |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Anticoagulants / antiplatelets (warfarin, aspirin, clopidogrel) | Additive bleeding-time increase | Physician coordination, especially at >3 g/day |
| High dose in AFib-prone people | The atrial-fibrillation risk is itself dose-dependent | Use the lowest effective dose; don't chase megadoses |
| Oxidized/low-quality fish oil | Rancid product delivers oxidative load that works against the anti-inflammatory goal | Buy third-party-tested for oxidation (TOTOX); store cold |
Personal results template
My Omega-3 results log
| Date | Week | Dose | Omega-3 index | hs-CRP | Triglycerides | Notes |
|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | — | Baseline |
| YYYY-MM-DD | 12 | 2–4 g EPA+DHA | — | — | — | Primary endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: Rising omega-3 index with improving hs-CRP and triglycerides. - No effect: No lab movement at 12 weeks — verify form (rTG vs ethyl ester) and fat co-ingestion before concluding it isn't working. - Stop and reassess: Unusual bruising or bleeding, or any allergic reaction.
Is krill oil worth the premium?
Fish oil triglycerides vs phospholipid-bound EPA/DHA — see the actual bioavailability trade-off before choosing a form.
Omega-3 vs Krill OilReferences
- REDUCE-IT Trial: High-Dose EPA Reduces Cardiovascular Events by 25%. New England Journal of Medicine (2018). PMID 30145934
- PMID 32835509
- PMID 22245710
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.